Paul G Rubinstein, Page C Moore, Milan Bimali, Jeanette Y Lee, Michelle A Rudek, Amy Chadburn, Lee Ratner, David H Henry, Ethel Cesarman, Camille E DeMarco, Dominique Costagliola, Yassine Taoufik, Juan Carlos Ramos, Elad Sharon, Erin G Reid, Richard F Ambinder, Ronald Mitsuyasu, Nicolas Mounier, Caroline Besson, Ariela Noy
BACKGROUND: Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been excluded from these studies. We aimed to understand the activity and safety of brentuximab vedotin-AVD in people living with HIV diagnosed with Hodgkin lymphoma, while focusing on HIV disease parameters and antiretroviral therapy (ART) interactions. METHODS: We present the phase 2 portion of a multicentre phase 1/2 study...
August 2023: Lancet Haematology